Research Coverage


Code: 4592Last Update:
Research Reports
Download Research Report

SanBio is a biotechnology company that develops regenerative cell medicines to restore nerve function lost due to disease or injury. Many companies are involved in regenerative medicine, including those involved in drug discovery and development, those specializing in production, and those selling related equipment and services. SanBio develops new drugs (cell medicines) that use allogeneic transplantation (see figure below). In terms of clinical development, SanBio is the most advanced company using regenerative cell medicines to treat central nervous system disorders. The company develops drug candidates internally through discovery and early clinical development, and then out-licenses the products to larger, multinational pharmaceutical companies.

Our Policy

We interview management for hours, asking exhaustive questions to uncover the essence of the business.

We pinpoint strengths and weaknesses, and discuss strategy. Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue.

Our Research

We start our coverage with a substantial core report. We then continuously update this report to reflect earnings, newsflow, and any material developments. We interview the management quarterly to help you stay on top of the story.

Our report is an authoritative Owner’s Manual of the company—a vital piece in the investor’s toolbox.

For Investors

If you find our efforts valuable, please tell companies you want them to join our growing client list.